SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced that the first patient was included in TOPOLOGY by investigator Dr. Delphine Loirat, with a Phase II clinical trial...
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced today that the first patient was treated with PLX038 (PEGylated SN-38) in a Phase I/II clinical trial for primary CNS tumors...
SAN FRANCISCO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc., a biotech company with a unique technology for tunable half-life extension of drugs, announced publication of a paper entitled Could...
SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian cancer at the Mayo Clinic. Mayo Clinic investigators Drs. Andrea E. Wahner Hendrickson and Scott H. Kaufmann are conducting the trial.
ProLynx, Inc., a biotechnology company with a novel platform technology for half-life extension of therapeutics, enabling novel and potentially best-in-class treatments to be developed, today announced that Richard King, MBA, has been appointed as Chief Executive Officer and as a member of the Board of Directors. Additionally, Chris Ehrlich, MBA, has joined the company as a member of the Board of Directors.
ProLynx, Inc., a biotechnology company with a novel platform technology for half-life extension of therapeutics, enabling novel and potentially best-in-class treatments to be developed, today announced that Richard King, MBA, has been appointed as Chief Executive Officer and as a member of the Board of Directors. Additionally, Chris Ehrlich, MBA, has joined the company as a member of the Board of Directors.
SAN FRANCISCO, July 07, 2020 (GLOBE NEWSWIRE) -- Today ProLynx announced it was awarded a Small Business Innovation Research (SBIR) grant from the NIH. The grant was conferred for the development of a long acting parathyroid hormone – PTH(1-34) – that can be administered once-weekly for treatment of hypo-parathyroidism. To achieve this, ProLynx will employ its platform half-life extension technology using its hydrogel microsphere carriers.